Clinical Trial Update: Phase 2 Study of Rapcabtagene Autoleucel in Myositis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating Racabtagene Autoleucel for idiopathic inflammatory myopathies (myositis) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Inflammatory Myopathies

Drugs mentioned

• Racabtagene Autoleucel (racabtagene autoleucel)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Idiopathic Inflammatory Myopathies | Phase 2 | Status: RECRUITING